Comparison of the analgesic effect of oral morphine with that of intravenous morphine in pediatric patients: multicenter open-label randomized blinded prospective clinical study

Abstract

BACKGROUND: Certain children with recurrent episodes of acute nociceptive pain experience chronic pain. In accordance with the recommendations of the World Health Organization, short-acting morphine is the main drug used to relieve severe pain and breakthrough pain. In published studies, morphine provided adequate analgesia in the majority (>90%) of the patients; however, no such studies have compared the use of morphine tablets with a control group of pediatric patients.

OBJECTIVE: To evaluate the effectiveness and safety of morphine tablets at a dose of 5 mg and compare them with those of morphine given intravenously at a dose of 10 mg/mL in children with severe pain syndrome in the postoperative period.

MATERIALS AND METHODS: A multicenter open randomized blind prospective clinical study was conducted in parallel groups of 100 patients aged 3–18 years with severe pain syndrome in the postoperative period between September 21, 2020, and December 15, 2022. Cumulative morphine consumption, visual analog scale analgesic efficacy, patient satisfaction scores, and adverse events (AEs) / serious adverse events (SAEs) were assessed.

RESULTS: The comparative analysis of the average values of the total number of doses of an additional analgesic drug administered during treatment with the study drug (group 1)/comparison drug (group 2) in patients of different age groups (cohorts 1, 2, 3) did not reveal significant differences (p=0.05). This finding indicated the equal effectiveness of the used forms of drugs in both groups. Moreover, no significant differences were noted in the development of AEs associated with the study drug (group 1) compared with AEs of the reference drug (group 2) in patients of different age groups (cohorts 1, 2, 3); (p=0.05).

CONCLUSION: The study demonstrated the effectiveness and safety of the study drug in tablets in comparison with an injection drug in children with severe pain syndrome.

Keywords

morphine / children / cancer pain / opioid / postoperative analgesia

References

[1] Friedrichsdorf SJ, Giordano J, Desai Dakoji K, et al. Chronic Pain in Children and Adolescents: Diagnosis and Treatment of Primary Pain Disorders in Head, Abdomen, Muscles and Joints. Children (Basel). 2016;3(4):42. doi: 10.3390/children3040042

[2] Friedrichsdorf S.J., Giordano J., Desai Dakoji K., et al. Chronic Pain in Children and Adolescents: Diagnosis and Treatment of Primary Pain Disorders in Head, Abdomen, Muscles and Joints // Children (Basel). 2016. Vol. 3, N 4. P. 42. doi: 10.3390/children3040042

[3] Rabbitts JA, Zhou C, Groenewald CB, et al. Trajectories of postsurgical pain in children: risk factors and impact of late pain recovery on long-term health outcomes after major surgery. Pain. 2015;156(11):2383–2389. doi: 10.1097/j.pain.0000000000000281

[4] Rabbitts J.A., Zhou C., Groenewald C.B., et al. Trajectories of postsurgical pain in children: risk factors and impact of late pain recovery on long-term health outcomes after major surgery // Pain. 2015. Vol. 156, N 11. P. 2383–2389. doi: 10.1097/j.pain.0000000000000281

[5] Kinoshita M, Olsson E, Borys F, Bruschettini M. Opioids for procedural pain in neonates. Cochrane Database Syst Rev. 2023;4(4):CD015056. doi: 10.1002/14651858.CD015056.pub2

[6] Kinoshita M., Olsson E., Borys F., Bruschettini M. Opioids for procedural pain in neonates // Cochrane Database Syst Rev. 2023. Vol. 4, N 4. CD015056. doi: 10.1002/14651858.CD015056.pub2

[7] The Association of Pediatric Palliative Medicine Master Formulary. United Kingdom: APPM; 2012.

[8] The Association of Pediatric Palliative Medicine Master Formulary. United Kingdom: APPM, 2012.

[9] WHO Guidelines on the Pharmacological Treatment of Persisting Pain in Children with Medical Illnesses. Geneva: World Health Organization; 2012.

[10] WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses. Geneva: World Health Organization, 2012.

[11] WHO model list of essential medicines for children — 4th list. Geneva: World Health Organization; 2013.

[12] WHO model list of essential medicines for children — 4th list. Geneva: World Health Organization, 2013.

[13] Mawatari H, Shinjo T, Morita T, et al. Revision of Pharmacological Treatment Recommendations for Cancer Pain: Clinical Guidelines from the Japanese Society of Palliative Medicine. J Palliat Med. 2022;25(7):1095–1114. doi: 10.1089/jpm.2021.0438

[14] Mawatari H., Shinjo T., Morita T., et al. Revision of Pharmacological Treatment Recommendations for Cancer Pain: Clinical Guidelines from the Japanese Society of Palliative Medicine // J Palliat Med. 2022. Vol. 25, N 7. P. 1095–1114. doi: 10.1089/jpm.2021.0438

[15] Harris JT, Suresh Kumar K, Rajagopal MR. Intravenous morphine for rapid control of severe cancer pain. Palliat Med. 2003;17(3):248–256. doi: 10.1191/0269216303pm695oa

[16] Harris J.T., Suresh Kumar K., Rajagopal M.R. Intravenous morphine for rapid control of severe cancer pain // Palliat Med. 2003. Vol. 17, N 3. P. 248–256. doi: 10.1191/0269216303pm695oa

[17] Wiffen PJ, Wee B, Moore RA. Oral morphine for cancer pain. Cochrane Database Syst Rev. 2016;4(4):CD003868. doi: 10.1002/14651858.CD003868.pub4

[18] Wiffen P.J., Wee B., Moore R.A. Oral morphine for cancer pain // Cochrane Database Syst Rev. 2016. Vol. 4, N 4. CD003868. doi: 10.1002/14651858.CD003868.pub4

[19] Wiffen PJ, Derry S, Moore RA. Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database Syst Rev. 2014;2014(5):CD011056. doi: 10.1002/14651858.CD011056.pub2

[20] Wiffen P.J., Derry S., Moore R.A. Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain // Cochrane Database Syst Rev. 2014. Vol. 2014, N 5. CD011056. doi: 10.1002/14651858.CD011056.pub2

[21] Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. US Department of Health and Human Services; 2017.

[22] Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. US Department of Health and Human Services, 2017.

[23] Abuzarova GR, Nevzorova DV, Kumirova EV, et al. Pain management for adults and children when providing medical care. Guidelines. Moscow: FGBOU VO RNIMU im. N.I. Pirogova; 2016. (In Russ).

[24] Абузарова Г.Р., Невзорова Д.В., Кумирова Э.В., и др. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. Москва: ФГБОУ ВО РНИМУ им. Н.И. Пирогова, 2016.

[25] Farrar JT, Portenoy RK, Berlin JA, et al. Defining the clinically important difference in pain outcome measures. Pain. 2000;88(3):287–294. doi: 10.1016/S0304-3959(00)00339-0

[26] Farrar J.T., Portenoy R.K., Berlin J.A., et al. Defining the clinically important difference in pain outcome measures // Pain. 2000. Vol. 88, N 3. P. 287–294. doi: 10.1016/S0304-3959(00)00339-0

[27] Ridgway D, Sopata M, Burneckis A, et al. Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study. J Pain Symptom Manage. 2010;39(4):712–720. doi: 10.1016/j.jpainsymman.2009.08.013

[28] Ridgway D., Sopata M., Burneckis A., et al. Clinical efficacy and safety of once-daily dosing of a novel, prolonged-release oral morphine tablet compared with twice-daily dosing of a standard controlled-release morphine tablet in patients with cancer pain: a randomized, double-blind, exploratory crossover study // J Pain Symptom Manage. 2010. Vol. 39, N 4. P. 712–720. doi: 10.1016/j.jpainsymman.2009.08.013

[29] Fortier MA, Chou J, Muarer EL, Kain ZN. Acute to chronic postoperative pain in children: preliminary findings. J Ped Surg. 2011;46(9):1700–1705. doi: 10.1016/j.jpedsurg.2011.03.074

[30] Fortier M.A., Chou J., Muarer E.L., Kain Z.N. Acute to chronic postoperative pain in children: preliminary findings // J Ped Surg. 2011. Vol. 46, N 9. P. 1700–1705. doi: 10.1016/j.jpedsurg.2011.03.074

Funding

ФГУП «Московский эндокринный завод»Federal State Unitary Enterprise "Moscow Endocrine Plant", Russia

RIGHTS & PERMISSIONS

Eco-Vector